# Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

> **NCT04181203** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 490 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **RADIATION:** Salvage radiotherapy (SRT)
- **DRUG:** Luteinising Hormone Releasing Hormone agonist (LHRHa)

## Key facts

- **NCT ID:** NCT04181203
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-09
- **Primary completion:** 2028-09-28
- **Final completion:** 2033-12-28
- **Target enrollment:** 490 (ESTIMATED)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04181203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04181203, "Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04181203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*